ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1220

Sjögren’s Patients’ Experiences and Content Validity of the Dry Eye Disease Symptom Questionnaire (DED-SQ)

Denise Kruzikas1, Ann Eldred2, Shelly Kafka3, Janet Church4, Katherine Hammitt4, Patricia Koochaki5 and Christina O'Donnell6, 1AbbVie, Inc., North Chicago, IL, 2AbbVie, Inc., Lake Bluff, IL, 3AbbVie, Inc., Norristown, PA, 4Sjögren’s Foundation, Reston, VA, 5ICON Clinical Research LLC, Raleigh, NC, 6ICON plc, Raleigh, NC

Meeting: ACR Convergence 2023

Keywords: Eye Disorders, Patient reported outcomes, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1200–1220) Patient Outcomes, Preferences, & Attitudes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Dry eye is one of the most important and prevalent symptoms experienced by patients with Sjögren’s Disease (SJD). The DED-SQ is a 12-item patient reported outcome (PRO) measure developed to assess dry eye disease. The purpose of this study was to identify the most important dry eye concepts to SJD patients and assess content validity of the DED-SQ for use in SJD populations.

Methods: Recruitment was conducted in partnership with the Sjögren’s Foundation, with patients self-selecting for participation. US patients with physician-confirmed diagnosis of SJD and symptoms of dry eye were recruited. Combined concept elicitation (CE) and cognitive interviews (CI) were conducted by phone or online platform with 29 adult SJD patients. During CE, patients reported the most important dry eye symptoms and the impact of dry eye on their daily lives and ability to function. During CI, patients completed the DED-SQ followed by discussion of the relevancy of items, clarity of wording, ease of completion, selection of response options, comprehensiveness, and appropriateness of the recall period. Interviews were audio recorded, transcribed, and anonymized. Thematic analysis of the CE data was conducted using MAXQDA, software designed to organize and facilitate qualitative data analysis, and a codebook, developed from the interview guide and supplemented with additional codes derived from patient comments. An item tracking matrix was used to facilitate a systematic evaluation of the individual items, instructions, recall period and response options to make recommendations for revision.

Results: The study participants were predominantly female (96%), White (79%), and held a bachelor’s degree or higher (90%). On average, participants were 62.8 years of age. Patients reported multiple symptoms of dry eye (Table 1), including general dryness (100%), pain, soreness, or an ache in their eyes (41%), as well as a gritty and/or sandy feeling in their eyes (45%). Patients also reported that dry eye caused their vision to be blurry, distorted, foggy, or fuzzy making it difficult to read text (38%). The reported dry eye symptom descriptions mapped well onto concepts/items in DED-SQ and patients found most items in the DED-SQ relevant to their experiences. Some patients suggested concepts that may be less relevant to SJD (“red eyes” (56%), “itchy eyes” (31%), or “crustiness” (52%) or that may be difficult to distinguish from causes other than SJD (“stinging/sharp feeling”, “burning” (28%)). Apart from items on stinging and burning, patients interpreted the items as intended (≥93%) and found the items easy to answer (≥81%). Patients felt the past 24-hour recall period was appropriate (82%).No additional dry eye symptoms beyond those included in the DED-SQ were identified.

Conclusion: These results reveal dry eye consists of a constellation of symptoms. A PRO covering the multifaceted concept of dry eye may be needed to appropriately assess SJD patients’ experiences. These findings suggest a revised DED-SQ may be fit-for-purpose for assessing dry eye in SJD. Further research can help assess the content validity of a revised DED-SQ in SJD patients.

Supporting image 1


Disclosures: D. Kruzikas: AbbVie/Abbott, 3, 11; A. Eldred: AbbVie/Abbott, 3, 11; S. Kafka: AbbVie/Abbott, 3, 11; J. Church: Sjögren’s Foundation, 3; K. Hammitt: Sjögren’s Foundation, 3; P. Koochaki: ICON Clinical Research LLC, 3, the healthcare business of Merck KGaA, Darmstadt, Germany, 2; C. O'Donnell: ICON plc, 3.

To cite this abstract in AMA style:

Kruzikas D, Eldred A, Kafka S, Church J, Hammitt K, Koochaki P, O'Donnell C. Sjögren’s Patients’ Experiences and Content Validity of the Dry Eye Disease Symptom Questionnaire (DED-SQ) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/sjogrens-patients-experiences-and-content-validity-of-the-dry-eye-disease-symptom-questionnaire-ded-sq/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sjogrens-patients-experiences-and-content-validity-of-the-dry-eye-disease-symptom-questionnaire-ded-sq/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology